Life Sciences Summit Will Showcase Immunomic Therapeutics

NEW YORK & ROCKVILLE, Md.–(BUSINESS WIRE)– On Wednesday, Nov. 2, Immunomic Therapeutics CEO, Dr. William Hearl will
speak on Immuno-oncology and the future of personalized medicine. The
panel will discuss immuno-oncology therapies applied to the most
difficult to treat cancers including metastatic kidney cancer,
metastatic melanoma, and lung cancer, among others. The panel will
explore top-of-mind questions on immunotherapies including why all
patients do not respond equally, or at all, and methods of predicting
effective therapies for diverse cases.

Who: Dr. William Hearl, CEO, Immunomic Therapeutics

What: Panel discussion titled Immuno-Oncology: Cracking the Code
of Personalized Medicine; open to conference attendees and media

When: Wednesday, Nov. 2, 1:15 pm EST

Where: 10 on the Park at Time Warner Center, 60 Columbus Circle 10^th
Floor, New York, New York. Please enter at the West 60^th St
entrance for 60 Columbus Circle (between Equinox Gym and The Mandarin
Oriental Hotel off Columbus Circle.) Bring photo ID.

About ITI

Immunomic Therapeutics, Inc. is a privately-held, clinical stage
biotech company on a mission to pioneer vaccines that transform lives.
The company, based in Rockville, MD, is developing nucleic acid vaccines
based on the patented Lysosomal Associated Membrane Protein (LAMP)
Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology
works with the body’s natural biochemistry system and has the potential
to improve a broad range of vaccines. ITI entered into a licensing
agreement with Astellas Pharma Inc. in 2015 to explore the use of
LAMP-Vax in the prevention and treatment of allergic diseases, and is
now focused on cancer immunotherapy. The LAMP platform has been tested
in Phase I and II clinical studies. For more information, please visit www.immunomix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005622/en/